PEG Ratio

Eli Lilly’s current PEG ratio of 0.25x means the stock’s price-to-earnings multiple is 0.25 times its expected earnings growth rate — a value below 1.0 typically signals that the stock is priced cheaply relative to its growth prospects.

This sits well below the healthcare sector median of 0.66x, placing LLY in the 24th percentile among its peers, indicating it is more attractively valued on a growth-adjusted basis than three-quarters of the sector. The metric has been stable over the last eight quarters, with a year-over-year increase of 13.6% and a quarter-over-quarter rise of 8.7%, showing a gentle upward drift rather than a sharp change. The combination of a low PEG ratio and a stable, slowly increasing trend suggests limited downside risk from valuation compression, but also no catalyst for rapid re-rating — creating a balanced risk/reward profile. This metric supports the overall NEUTRAL verdict because the favorable valuation is offset by the absence of accelerating growth momentum that would justify a more bullish stance.

Frequently Asked Questions

Closest Sector Peers